Header Logo

Parameswaran Venugopal

Concepts (236)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Combined Chemotherapy Protocols
19
2023
329
1.870
Why?
Leukemia, Myeloid, Acute
5
2021
45
1.270
Why?
Lymphoma, Non-Hodgkin
8
2019
42
1.260
Why?
Arabinonucleosides
4
2021
6
1.030
Why?
Lymphoma, Large B-Cell, Diffuse
6
2019
24
1.020
Why?
Lymphoma
3
2023
44
1.010
Why?
Central Nervous System Neoplasms
3
2023
13
1.000
Why?
Antibodies, Monoclonal
8
2011
270
0.990
Why?
Rituximab
16
2023
54
0.980
Why?
Antibodies, Monoclonal, Murine-Derived
11
2017
38
0.800
Why?
Antineoplastic Agents
5
2022
250
0.800
Why?
Adenine Nucleotides
2
2010
2
0.730
Why?
Burkitt Lymphoma
3
2021
7
0.590
Why?
Paraproteinemias
2
2019
5
0.570
Why?
Insulin-Like Growth Factor Binding Proteins
1
2015
11
0.520
Why?
Insulin-Like Growth Factor I
1
2015
55
0.500
Why?
Middle Aged
25
2023
9959
0.480
Why?
Treatment Outcome
18
2021
3558
0.470
Why?
Adult
21
2021
8774
0.460
Why?
Humans
43
2023
29889
0.450
Why?
Aged
22
2023
9620
0.430
Why?
Male
25
2022
15874
0.410
Why?
Cyclophosphamide
9
2021
56
0.410
Why?
Necrobiotic Xanthogranuloma
1
2011
1
0.400
Why?
Plasma Cells
1
2011
8
0.400
Why?
Mediastinum
1
2011
6
0.400
Why?
Lymphoma, Mantle-Cell
1
2011
6
0.400
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2022
18
0.380
Why?
Doxorubicin
7
2021
70
0.360
Why?
Arsenicals
2
2007
9
0.360
Why?
Oxides
2
2007
13
0.360
Why?
Female
26
2021
16474
0.360
Why?
Cranial Irradiation
2
2007
13
0.350
Why?
Vincristine
7
2019
27
0.340
Why?
Aged, 80 and over
11
2023
4932
0.340
Why?
Prednisone
7
2019
68
0.330
Why?
Lymphohistiocytosis, Hemophagocytic
1
2008
8
0.320
Why?
Cachexia
2
2019
11
0.320
Why?
Disease-Free Survival
7
2021
191
0.310
Why?
Kaplan-Meier Estimate
5
2021
177
0.310
Why?
Leukemia, Myelomonocytic, Acute
1
2007
1
0.300
Why?
Sarcoma, Myeloid
1
2007
4
0.300
Why?
Ear Neoplasms
1
2007
6
0.290
Why?
Lymphoproliferative Disorders
2
2023
19
0.290
Why?
Recurrence
6
2020
353
0.280
Why?
Epstein-Barr Virus Infections
2
2023
19
0.280
Why?
Brain Neoplasms
2
2006
134
0.280
Why?
Purpura, Thrombotic Thrombocytopenic
1
2006
11
0.270
Why?
Drug Administration Schedule
6
2019
232
0.270
Why?
Combined Modality Therapy
4
2019
379
0.250
Why?
Biomarkers
3
2019
703
0.250
Why?
Immunotherapy
2
2008
66
0.240
Why?
Prognosis
6
2021
878
0.240
Why?
Lymphomatoid Granulomatosis
1
2003
3
0.230
Why?
HIV Infections
2
2021
997
0.230
Why?
Lymphoma, B-Cell
3
2008
10
0.230
Why?
Proto-Oncogene Proteins c-myc
2
2021
21
0.220
Why?
Remission Induction
6
2015
103
0.210
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
3
2011
22
0.200
Why?
Drug Resistance, Neoplasm
3
2020
77
0.190
Why?
Thrombosis
1
2021
59
0.190
Why?
Deubiquitinating Enzymes
1
2020
2
0.180
Why?
Benzylidene Compounds
1
2020
2
0.180
Why?
Azepines
1
2020
7
0.180
Why?
Retrospective Studies
5
2023
3325
0.180
Why?
Multiple Myeloma
1
2020
30
0.180
Why?
Graft vs Host Disease
1
2020
47
0.180
Why?
Folic Acid Deficiency
1
2019
6
0.170
Why?
Phthalazines
1
2019
8
0.170
Why?
Respiratory Insufficiency
1
2020
50
0.170
Why?
Young Adult
4
2021
1968
0.170
Why?
Central Nervous System
3
2023
57
0.170
Why?
Proportional Hazards Models
2
2017
346
0.170
Why?
Hematopoietic Stem Cell Transplantation
1
2020
92
0.170
Why?
Proto-Oncogene Proteins c-bcl-2
1
2019
30
0.170
Why?
Neutropenia
4
2012
21
0.160
Why?
Piperazines
1
2019
93
0.160
Why?
Cytosine
2
2021
6
0.160
Why?
Neoplasm Recurrence, Local
3
2021
200
0.160
Why?
Medical Oncology
1
2018
36
0.160
Why?
Kidney Diseases
1
2019
117
0.150
Why?
Cardiology
1
2018
73
0.150
Why?
Immunity
1
2017
24
0.150
Why?
Bendamustine Hydrochloride
1
2016
4
0.150
Why?
Immunocompromised Host
1
2017
45
0.140
Why?
Stroke Volume
1
2016
59
0.140
Why?
Biopsy
2
2019
240
0.130
Why?
Registries
1
2017
191
0.130
Why?
Feasibility Studies
2
2019
230
0.130
Why?
Induction Chemotherapy
1
2015
14
0.130
Why?
Hematologic Neoplasms
1
2014
17
0.120
Why?
Myelodysplastic Syndromes
2
2004
38
0.120
Why?
Metabolic Syndrome
1
2014
67
0.120
Why?
Leukopenia
2
2011
9
0.110
Why?
Lymphoma, Follicular
2
2011
4
0.110
Why?
Herpesvirus 4, Human
2
2023
14
0.110
Why?
Methotrexate
2
2023
43
0.110
Why?
Transcription Factors
2
2004
166
0.110
Why?
Cytarabine
3
2023
10
0.110
Why?
Daunorubicin
2
2015
5
0.110
Why?
Transcriptome
1
2012
84
0.100
Why?
DNA-Binding Proteins
2
2004
263
0.100
Why?
Hemoglobinuria, Paroxysmal
1
2012
7
0.100
Why?
Diabetes Mellitus, Type 2
1
2014
202
0.100
Why?
Obesity
1
2014
290
0.100
Why?
Agranulocytosis
1
2011
5
0.100
Why?
Yttrium Radioisotopes
1
2011
5
0.100
Why?
Lymphoma, B-Cell, Marginal Zone
1
2011
6
0.100
Why?
Fatal Outcome
2
2008
60
0.100
Why?
Retreatment
1
2010
14
0.090
Why?
Salvage Therapy
1
2010
36
0.090
Why?
Cytokines
1
2012
349
0.090
Why?
Pilot Projects
1
2011
403
0.090
Why?
Platelet Count
2
2007
22
0.090
Why?
Infusions, Intravenous
2
2020
78
0.080
Why?
Weight Loss
2
2019
101
0.070
Why?
Tretinoin
1
2007
15
0.070
Why?
Injections, Spinal
1
2007
53
0.070
Why?
Tomography, X-Ray Computed
1
2011
777
0.070
Why?
Vascular Neoplasms
1
2006
3
0.070
Why?
ADAMTS13 Protein
1
2006
5
0.070
Why?
Follow-Up Studies
1
2011
1856
0.070
Why?
Plasma Exchange
1
2006
15
0.070
Why?
Severity of Illness Index
2
2021
1126
0.070
Why?
ADAM Proteins
1
2006
65
0.070
Why?
Immunosuppressive Agents
2
2023
135
0.070
Why?
Hemoglobins
1
2006
83
0.060
Why?
Autoantibodies
1
2006
105
0.060
Why?
Twins, Dizygotic
1
2005
4
0.060
Why?
Survival Analysis
2
2019
310
0.060
Why?
Radiography
1
2007
678
0.060
Why?
Proto-Oncogenes
1
2004
4
0.060
Why?
Thalidomide
1
2004
7
0.060
Why?
Kidney Transplantation
1
2006
126
0.060
Why?
Cohort Studies
2
2021
1954
0.060
Why?
United States
2
2021
2345
0.060
Why?
Etoposide
2
2019
50
0.060
Why?
Peripheral Blood Stem Cell Transplantation
1
2004
3
0.060
Why?
Antigens, CD20
1
2003
5
0.060
Why?
Epilepsy, Tonic-Clonic
1
2003
9
0.060
Why?
Vision Disorders
1
2003
24
0.060
Why?
Antigens, Neoplasm
1
2003
45
0.060
Why?
Cyclin D1
1
2003
5
0.060
Why?
Cell Cycle Proteins
1
2003
17
0.060
Why?
K562 Cells
1
2003
6
0.060
Why?
Telomerase
1
2003
10
0.060
Why?
Histones
1
2003
28
0.060
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2022
1
0.050
Why?
Voriconazole
1
2022
8
0.050
Why?
Apoptosis
1
2003
258
0.050
Why?
Cerebral Cortex
1
2003
197
0.050
Why?
Sulfonamides
1
2022
60
0.050
Why?
Azacitidine
1
2021
12
0.050
Why?
United Kingdom
1
2021
51
0.050
Why?
Risk Factors
2
2005
2466
0.050
Why?
L-Lactate Dehydrogenase
1
2021
8
0.050
Why?
Gene Rearrangement
1
2021
11
0.050
Why?
Incidence
1
2023
761
0.050
Why?
Thrombocytopenia
2
2012
31
0.040
Why?
Postoperative Complications
1
2006
957
0.040
Why?
Activities of Daily Living
1
2023
507
0.040
Why?
Folic Acid
1
2019
16
0.040
Why?
Monoclonal Gammopathy of Undetermined Significance
1
2019
2
0.040
Why?
Kidney Function Tests
1
2019
23
0.040
Why?
Maintenance Chemotherapy
1
2019
1
0.040
Why?
Translocation, Genetic
1
2019
9
0.040
Why?
Maximum Tolerated Dose
1
2019
20
0.040
Why?
Immunoglobulin A
1
2019
19
0.040
Why?
Symptom Assessment
1
2019
21
0.040
Why?
Transplantation, Homologous
1
2020
279
0.040
Why?
Vidarabine
2
2011
11
0.040
Why?
Anemia
2
2012
98
0.040
Why?
Body Composition
1
2019
56
0.040
Why?
Ovarian Neoplasms
1
2019
49
0.040
Why?
Sarcopenia
1
2019
26
0.040
Why?
Mitoxantrone
2
2011
5
0.040
Why?
Interdisciplinary Communication
1
2018
28
0.040
Why?
Cardiologists
1
2018
14
0.040
Why?
Magnetic Resonance Imaging
1
2003
1247
0.040
Why?
Lung Neoplasms
1
2003
636
0.040
Why?
Disease Management
1
2019
123
0.040
Why?
Bortezomib
1
2017
5
0.040
Why?
Sex Factors
1
2019
498
0.040
Why?
Tomography, Emission-Computed
2
2006
11
0.040
Why?
Prospective Studies
2
2015
1837
0.030
Why?
Disease Progression
2
2012
812
0.030
Why?
Neoplasms
1
2019
257
0.030
Why?
Recombinant Proteins
2
2008
257
0.030
Why?
Naphthalimides
1
2015
2
0.030
Why?
Adenine
1
2015
5
0.030
Why?
Organophosphonates
1
2015
5
0.030
Why?
Adolescent
1
2021
2335
0.030
Why?
Lipid Metabolism
1
2014
31
0.030
Why?
Sensitivity and Specificity
2
2006
558
0.030
Why?
Insulin Resistance
1
2014
61
0.030
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2004
154
0.030
Why?
Cytogenetic Analysis
1
2012
6
0.030
Why?
RNA, Messenger
2
2003
324
0.030
Why?
Administration, Oral
1
2012
144
0.030
Why?
Pneumonia
1
2012
67
0.030
Why?
Signal Transduction
1
2014
494
0.030
Why?
Radiopharmaceuticals
1
2011
53
0.020
Why?
Time Factors
1
2015
1642
0.020
Why?
Nausea
1
2007
28
0.020
Why?
Creatinine
1
2007
44
0.020
Why?
Methylprednisolone
1
2007
24
0.020
Why?
Cisplatin
1
2007
92
0.020
Why?
Animals
1
2014
4638
0.020
Why?
Dose-Response Relationship, Drug
1
2006
455
0.020
Why?
MDS1 and EVI1 Complex Locus Protein
1
2004
3
0.020
Why?
Zinc Fingers
1
2004
10
0.020
Why?
Cell Lineage
1
2004
30
0.020
Why?
Spleen
1
2004
54
0.020
Why?
Teniposide
1
2004
2
0.020
Why?
Bleomycin
1
2004
2
0.020
Why?
Neoplasm Staging
1
2005
364
0.010
Why?
Drug Therapy, Combination
1
2004
247
0.010
Why?
Interferon-alpha
1
2004
69
0.010
Why?
S Phase
1
2003
10
0.010
Why?
E2F Transcription Factors
1
2003
5
0.010
Why?
E2F1 Transcription Factor
1
2003
5
0.010
Why?
Retinoblastoma Protein
1
2003
10
0.010
Why?
Transplantation, Autologous
1
2004
197
0.010
Why?
Karyotyping
1
2003
13
0.010
Why?
Patient Selection
1
2005
235
0.010
Why?
Granulocytes
1
2003
23
0.010
Why?
DNA Primers
1
2003
54
0.010
Why?
In Situ Hybridization, Fluorescence
1
2003
32
0.010
Why?
Bone Marrow Cells
1
2003
58
0.010
Why?
Cell Nucleus
1
2003
82
0.010
Why?
Transcription, Genetic
1
2003
107
0.010
Why?
Blotting, Western
1
2003
175
0.010
Why?
Polymerase Chain Reaction
1
2003
165
0.010
Why?
Bone Marrow
1
2003
78
0.010
Why?
Acute Disease
1
2003
225
0.010
Why?
Immunohistochemistry
1
2003
414
0.010
Why?
Venugopal's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (236)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_